Background Changes in glucidic metabolism characteristic of diabetes are a contributing factor in causing vulvovaginal candidiasis.

Purpose The objective of this study was evaluating the prevalence of morbidity through vaginal candidiasis with Candida albicans in diabetic women and instituting of specific antifungal therapy.

Materials and methods The study was conducted on 140 women (aged between 22-40 years) with diabetes, admitted in the Diabetes and Nutrition diseases clinic from Clinical Emergency Hospital of Craiova, Romania, from who were harvested blood and vaginal secretions. Blood sugar levels were determined by biochemical methods. The vaginal secretions were subjected to mycological diagnosis (Gram stain, isolation on Sabouraud media, identification by using chromogenic differential media specific for Candida). The isolates strains were subjected to fungal sensitivity test, using commercial kits: ATB Fungus 3 (BioMerieux, Marcy l’Étoile, France) and Candifast (EliTech France SAS) (5-Fluorocytosine, Amphotericin B, Fluconazole Itraconazole, Voriconazole, Econazole, Miconazole, Ketoconazole and Nystatin). The data was analysed using the Student's t-test.

Results The authors isolated 98 strains of Candida albicans, thus the morbidity by candidiasis was 70%, most of the patients had blood sugar levels between 130–180 mg/dl. The condition was more common in patients aged between 51-60 years (39.80%) and 41-50 years (31.63%). The results of antifungigram showed susceptibility to: Ketoconazole (95.92%), Econazole (89.80%), Fluconazole (85.71%) and Itraconazole (85.71%).

Conclusions These results demonstrate the existence of a correlation between hyperglycaemia and vaginal candidiasis. Most of the vulvovaginal candidiases were treated successfully with new antifungal drugs. Although regarded as a banal infection by some, the increased incidence of vaginal candidiasis associated with diabetes raises additional issues regarding prevention and patient management.